KR102937044B1 - Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 - Google Patents

Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도

Info

Publication number
KR102937044B1
KR102937044B1 KR1020227037880A KR20227037880A KR102937044B1 KR 102937044 B1 KR102937044 B1 KR 102937044B1 KR 1020227037880 A KR1020227037880 A KR 1020227037880A KR 20227037880 A KR20227037880 A KR 20227037880A KR 102937044 B1 KR102937044 B1 KR 102937044B1
Authority
KR
South Korea
Prior art keywords
azabicyclo
mmol
alkyl
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227037880A
Other languages
English (en)
Korean (ko)
Other versions
KR20230007352A (ko
Inventor
아키토 가쿠우치
슈헤이 우메무라
마사키 아사다
아나톨리 루빈스키
얀 장
히데노리 다카하시
고란 크리로프
다이고 이노야마
카일 콘제
매츠 스벤손
Original Assignee
오노 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오노 야꾸힝 고교 가부시키가이샤 filed Critical 오노 야꾸힝 고교 가부시키가이샤
Priority to KR1020267006670A priority Critical patent/KR20260046494A/ko
Publication of KR20230007352A publication Critical patent/KR20230007352A/ko
Application granted granted Critical
Publication of KR102937044B1 publication Critical patent/KR102937044B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227037880A 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 Active KR102937044B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267006670A KR20260046494A (ko) 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088925 2020-05-07
CN2020088925 2020-05-07
PCT/CN2021/091843 WO2021223699A1 (en) 2020-05-07 2021-05-06 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267006670A Division KR20260046494A (ko) 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도

Publications (2)

Publication Number Publication Date
KR20230007352A KR20230007352A (ko) 2023-01-12
KR102937044B1 true KR102937044B1 (ko) 2026-03-09

Family

ID=76159223

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227037880A Active KR102937044B1 (ko) 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도
KR1020267006670A Pending KR20260046494A (ko) 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267006670A Pending KR20260046494A (ko) 2020-05-07 2021-05-06 Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도

Country Status (13)

Country Link
US (3) US11691968B2 (cg-RX-API-DMAC7.html)
EP (2) EP4471027A1 (cg-RX-API-DMAC7.html)
JP (3) JP7643466B2 (cg-RX-API-DMAC7.html)
KR (2) KR102937044B1 (cg-RX-API-DMAC7.html)
CN (1) CN115461338B (cg-RX-API-DMAC7.html)
AU (1) AU2021268223C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022005A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181604A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037418T3 (cg-RX-API-DMAC7.html)
IL (1) IL297900B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013692A (cg-RX-API-DMAC7.html)
TW (1) TWI895412B (cg-RX-API-DMAC7.html)
WO (1) WO2021223699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof
JP2023070165A (ja) * 2021-11-05 2023-05-18 小野薬品工業株式会社 アザビシクロ環化合物の結晶
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Kdm5阻害作用を有する化合物を含有する医薬組成物
TW202612686A (zh) * 2024-05-17 2026-04-01 日商小野藥品工業股份有限公司 失智症之行動及心理症狀之預防、進展抑制及/或治療劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2021010492A1 (en) 2019-07-17 2021-01-21 Ono Pharmaceutical Co., Ltd. Compound having kdm5 inhibitory activity and pharmaceutical use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2021010492A1 (en) 2019-07-17 2021-01-21 Ono Pharmaceutical Co., Ltd. Compound having kdm5 inhibitory activity and pharmaceutical use thereof

Also Published As

Publication number Publication date
BR112022022005A2 (pt) 2022-12-13
CN115461338B (zh) 2024-02-20
US12269817B2 (en) 2025-04-08
JP7643466B2 (ja) 2025-03-11
US20230109293A1 (en) 2023-04-06
US20250214984A1 (en) 2025-07-03
CN115461338A (zh) 2022-12-09
JP7643632B2 (ja) 2025-03-11
MX2022013692A (es) 2022-11-30
KR20260046494A (ko) 2026-04-07
JP2025081677A (ja) 2025-05-27
EP4471027A1 (en) 2024-12-04
JP2024177345A (ja) 2024-12-19
KR20230007352A (ko) 2023-01-12
EP4146645B1 (en) 2025-06-25
IL297900B2 (en) 2026-04-01
US20230271952A1 (en) 2023-08-31
EP4146645A1 (en) 2023-03-15
ES3037418T3 (en) 2025-10-01
AU2021268223C1 (en) 2026-07-09
IL297900A (en) 2023-01-01
NZ793960A (en) 2025-12-19
JP2023524547A (ja) 2023-06-12
AU2021268223B2 (en) 2025-10-09
WO2021223699A1 (en) 2021-11-11
CA3181604A1 (en) 2021-11-11
TW202200571A (zh) 2022-01-01
AU2021268223A1 (en) 2022-12-08
US11691968B2 (en) 2023-07-04
IL297900B1 (en) 2025-12-01
TWI895412B (zh) 2025-09-01

Similar Documents

Publication Publication Date Title
US12269817B2 (en) Compound having KDM5 inhibitory activity and pharmaceutical use thereof
JP7786517B2 (ja) Kdm5阻害活性を有する化合物およびその医薬用途
JP7647552B2 (ja) Ep2アンタゴニスト
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
WO2022138793A1 (ja) Ep2受容体拮抗薬と免疫チェックポイント阻害薬および/またはep4受容体拮抗薬との組み合わせ
JP2024128038A (ja) Abhd6アンタゴニスト
JP6922712B2 (ja) 医薬用途
RU2840256C1 (ru) Соединение, обладающее ингибирующей активностью в отношении kdm5, и его фармацевтическое применение
JP7743829B2 (ja) Kdm5阻害作用を有する化合物を含有する医薬組成物
KR20230065914A (ko) Kdm5 억제 활성을 갖는 화합물을 포함하는 약학 조성물
TWI907744B (zh) 包含具有kdm5抑制活性之化合物之醫藥組合物
HK40083699A (en) 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
HK40083699B (en) 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
RU2857204C2 (ru) Антагонист abhd6
JP2022101520A (ja) Ep2アンタゴニストを含有する医薬組成物
JP2024052624A (ja) Abhd6アンタゴニストを含有する医薬組成物
HK40067217A (en) Ep2 antagonist

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)